Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

SAGE Therapeutics

Thumbnail
December 17, 2020

Key upcoming clinical catalysts for biotech

Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.

Thumbnail
November 30, 2020

Biogen’s Sage advice amounts to $1.5bn

Sage gets a big endorsement for zuranolone, but the markets say it should have waited until it had a stronger negotiating position.

Article image
Vantage logo
July 09, 2020

Biopharma shares shake off the pandemic

Global drug stocks enthusiastically joined the recovery on the financial markets in the second quarter, more than offsetting earlier declines.

Article image
Vantage logo
June 24, 2020

Important catalysts approach for smaller biotechs

Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.

Article image
Vantage logo
December 24, 2019

Intra-cellular triples on schizophrenia approval

Article image
Vantage logo
December 05, 2019

Sage advice: psychiatric drug development is tough

As a phase III blow-up brings Sage Therapeutics’ run of success to an end, the company’s post-hoc analyses fail to reassure investors that its depression project has a…

Article image
Vantage logo
October 04, 2019

Upcoming events – Sage targets depression and Biogen aims for lupus

Sage's big depression readout looms, while Biogen hopes for a mid-stage hit in lupus.

Article image
Vantage logo
September 24, 2019

Does amount matter when it comes to a biotech IPO?

Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.

Article image
Vantage logo
July 23, 2019

Marinus leaves the way clear for Sage

In the wake of a clinical trial failure Marinus plays down oral ganaxolone, but investors are unimpressed.

Article image
Vantage logo
June 18, 2019

Array-size deals don’t come around too often

Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.

Article image
Vantage logo
April 23, 2019

Splitting the difference on promising pipeline asset predictions

An analysis looking at forecast discrepancies for the top pipeline projects reveals vast differences of opinion about Vertex's cystic fibrosis triplet and Novo…

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.